Corcept Therapeutics
CORT
209 hedge funds and large institutions have $1.94B invested in Corcept Therapeutics in 2021 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 61 increasing their positions, 89 reducing their positions, and 37 closing their positions.
10% more call options, than puts
Call options by funds: $12.5M | Put options by funds: $11.4M
2.2% less ownership
Funds ownership: 71.78% → 69.59% (-2.2%)
8% less funds holding
Funds holding: 226 → 209 (-17)
11% less capital invested
Capital invested by funds: $2.18B → $1.94B (-$240M)
31% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 89
38% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 37
71% less funds holding in top 10
Funds holding in top 10: 7 → 2 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$16.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.5M |
| 3 |
BTW
Boston Trust Walden
Boston,
Massachusetts
|
+$9.63M |
| 4 |
AWS
AJ Wealth Strategies
New York
|
+$7.23M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
+$4.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$15.2M |
| 2 |
ISL
Ingalls & Snyder LLC
New York
|
-$9.49M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
-$8.72M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$7.54M |
| 5 |
D.E. Shaw & Co
New York
|
-$6.85M |
CORT Hedge Fund Activity: Q1 2021 in Review
209 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q1 2021, worth a combined $1.94B — down 11% from $2.18B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of CORT and 23 opened new positions — a net loss of 14 holders — while 89 trimmed existing stakes and 61 added.
The largest buyer was BlackRock, adding an estimated $16.7M. The largest seller was Renaissance Technologies, cutting an estimated $15.2M.
- 209 institutional investors held Corcept Therapeutics (CORT) as of Q1 2021, down from 226 in Q4 2020.
- Funds reported $1.94B of Corcept Therapeutics stock for Q1 2021, down 11% quarter-over-quarter.
- 23 funds opened new Corcept Therapeutics positions in Q1 2021 and 37 closed out, a net change of -14 holders.
- The largest Corcept Therapeutics buyer in Q1 2021 was BlackRock, an estimated $16.7M added.
- The largest Corcept Therapeutics seller in Q1 2021 was Renaissance Technologies, an estimated $15.2M sold.
Based on aggregated 13F filings for Q1 2021.